Right now, our biggest challenge is that theyre not necessarily convinced that by investing up front in these medications to treat obesity upstream, it will offset the cost of treating the medical conditions related to weight downstream. According to Novo Nordisk, about 50 million Americans with obesity should be able to access Wegovy through insurance
This is the legitimately useful, objective core of the article: the arithmetic that converts a dry vial into a known concentration
Will tirzepatide cure my autoimmune condition
By keeping up with coffee research for cancer patients, you can help manage side effects
Dr Hungerford says we need more long-term, large-scale studies to see how these medications impact people living with eating disordersincluding what happens when they stop using them as weight gain can be triggering for someone experiencing, or at risk of developing, an eating disorder